Literature DB >> 22544013

A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation.

Kai MacDonald1, Michael Wilson, Arpi Minassian, Gary M Vilke, Olga Becker, Kimberly Tallian, Patrice Cobb, Rachel Perez, Barbara Galangue, David Feifel.   

Abstract

OBJECTIVE: Published research on agitation is limited by the difficulty in generalizing findings from trials using moderately agitated, carefully selected patients treated with single agents. More specifically, there are few comparative studies examining common intramuscular (IM) regimens (ie, haloperidol with or without benzodiazepines) with IM atypical antipsychotics. Therefore, we conducted a retrospective chart review to compare IM olanzapine and haloperidol in a "real-world" population with agitation.
METHOD: We performed a retrospective evaluation of charts from 146 consecutive emergency department patients who received either IM haloperidol or IM olanzapine for agitation. We used a clinically oriented proxy marker of efficacy--the necessity for additional medication intervention for agitation (AMI)--as our primary outcome measure.
RESULTS: Additional medication intervention for agitation was required by 43% (13/30) patients when haloperidol was given alone and by 18% (13/72) when haloperidol was given with a benzodiazepine. In the case of olanzapine, AMI was required by 29% (6/21) of patients receiving olanzapine alone and by 18% (2/11) of patients given olanzapine plus a benzodiazepine. A significant percentage of patients had clinical characteristics (nonpsychiatric triage complaint, drug/alcohol use, severe agitation) that differ from more selective samples.
CONCLUSIONS: Overall, these finding suggest that in a naturalistic emergency department setting, haloperidol monotherapy is less effective--at least in requiring AMI--than olanzapine with or without a benzodiazepine or haloperidol plus a benzodiazepine. Moreover, these later 3 regimens seemed comparable. Prospective studies examining the treatment of real-world agitation, including head-to-head comparisons of the haloperidol-benzodiazepine combination with newer IM antipsychotics, are needed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544013     DOI: 10.1097/JCP.0b013e318253a2fe

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  5 in total

Review 1.  Management of Violence and Aggression in Emergency Environment; a Narrative Review of 200 Related Articles.

Authors:  Maryam Ziaei; Ali Massoudifar; Ali Rajabpour-Sanati; Ali-Mohammad Pourbagher-Shahri; Ali Abdolrazaghnejad
Journal:  Adv J Emerg Med       Date:  2018-11-29

2.  A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in agitated elderly patients with schizophrenia.

Authors:  Hidenobu Suzuki; Keishi Gen; Yuki Takahashi
Journal:  Ther Adv Psychopharmacol       Date:  2013-12

Review 3.  A Research Agenda for Assessment and Management of Psychosis in Emergency Department Patients.

Authors:  Jennifer Peltzer-Jones; Kimberly Nordstrom; Glenn Currier; Jon S Berlin; Cynthia Singh; Sandra Schneider
Journal:  West J Emerg Med       Date:  2019-02-19

4.  Brazilian guidelines for the management of psychomotor agitation. Part 2. Pharmacological approach.

Authors:  Leonardo Baldaçara; Alexandre P Diaz; Verônica Leite; Lucas A Pereira; Roberto M Dos Santos; Vicente de P Gomes Júnior; Elie L B Calfat; Flávia Ismael; Cintia A M Périco; Deisy M Porto; Carlos E K Zacharias; Quirino Cordeiro; Antônio Geraldo da Silva; Teng C Tung
Journal:  Braz J Psychiatry       Date:  2019-03-07       Impact factor: 2.697

5.  Intramuscular midazolam, olanzapine, or haloperidol for the management of acute agitation: A multi-centre, double-blind, randomised clinical trial.

Authors:  Esther W Chan; Kim S J Lao; Lam Lam; Sik-Hon Tsui; Chun-Tat Lui; Chi-Pang Wong; Colin A Graham; Chi-Hung Cheng; Tong-Shun Chung; Hiu-Fung Lam; Soo-Moi Ting; Jonathan C Knott; David M Taylor; David C M Kong; Ling-Pong Leung; Ian C K Wong
Journal:  EClinicalMedicine       Date:  2021-02-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.